ClinicalTrials.gg
Active, not recruitingNCT06630559Updated Feb 23, 2026

A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis

A Phase 3 interventional study of CT-P55 and EU-approved Cosentyx in Plaque Psoriasis, sponsored by Celltrion. Active, not recruiting at 1 site in Poland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-23.

Sponsored by Celltrion · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 166 studies in Psoriasis with a site in Poland — 7 open to participants now, 20 under way, 18 of them phase 3. Psoriasis · Poland.

Enrollment
128th of 162
153 · median 376
Started
2025
with 11 others
Phase 3
106 of 166
5 open now
Primary completion
2026-02
later than 8 of 19 live
Registered
156th of 166
by date

Among the 166 studies in Psoriasis with a site in Poland, this one is the 128th largest by enrollment of the 162 interventional ones that give a count, is one of 12 that started in 2025, is one of 106 in phase 3, reaches primary completion later than 8 of the 19 other live ones, and was the 156th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

7 of the 166 studies in Psoriasis with a site in Poland are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies in Psoriasis with a site in Poland, or all of them as a file.
02

Study summary

The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P55 with Cosentyx in patients with moderate to severe plaque psoriasis

Read the detailed description

CT-P55 is a recombinant humanized monoclonal antibody containing the active ingredient secukinumab. CT-P55 is a drug product being developed by CELLTRION, Inc. and being compared to the EU-approved Cosentyx®. In this study, Efficacy and Safety of CT-P55 will be evaluated in patients with Moderate to Severe Chronic Plaque Psoriasis.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Patient has had a diagnosis of chronic plaque psoriasis for at least 24 weeks.

Exclusion criteria

Exclusion Criteria:

  • Patient diagnosed with forms of psoriasis other than chronic plaque-type or medication-induced psoriasis.
  • Patient who has previously received Secukinumab or any other biologic drug directly targeting Interleukin-17 or the IL-17 receptor.
  • Patient who has allergies to any of the of study drug or materials of device or any other murine and human proteins, or patient with a to immunoglobulin products.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    CT-P55

    Biological: CT-P55

  • Active comparator
    EU-approved Cosentyx

    Biological: CT-P55 · Biological: EU-approved Cosentyx

Interventions

  • BiologicalCT-P55

    CT-P55, 300 mg by 2 subcutaneous (SC) injections of 150 mg/mL via Pre-Filled Syringe (PFS) every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by every 4 weeks (Q4W) for 11doses (up to Week 48).

  • BiologicalEU-approved Cosentyx

    European Union (EU)-approved Cosentyx, 300 mg by 2 SC injections of 150 mg/mL via PFS every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by Q4W for 11 doses (up to Week 48).

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in Psoriasis Area and Severity Index (PASI) score

    A higher percent change indicates a better outcome. While the maximum value is 100%, the minimum value is not fixed and may be negative in cases of worsening symptoms.

    Time frame: Week8

Secondary outcomes

  1. Actual PASI scores

    Minimum 0 to Maximum 72 Higher scores mean a worse outcome

    Time frame: Up to 56 Weeks

  2. Percent change from baseline in PASI score

    A higher percent change indicates a better outcome. While the maximum value is 100%, the minimum value is not fixed and may be negative in cases of worsening symptoms.

    Time frame: Up to 56 Weeks

  3. Proportion of patients who achieve at least 50/75/90/100% improvement from baseline in PASI (PASI 50/75/90/100)

    Time frame: Up to 56 Weeks

  4. Proportion of patients with Investigator's Global Assessment (IGA) score of clear (0) or almost clear (1)

    Time frame: Up to 56 Weeks

  5. Change from baseline in Dermatology Life Quality Index (DLQI)

    Minimum -30 to Maximum of 30 Higher scores indicate a worse outcome

    Time frame: Up to 56 Weeks

07

Study locations

1 site
  • Rheumatology Clinic NZOZ Lecznica MAK-MED s.c.
    Nadarzyn, Poland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Feb 2026, 8 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 8 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2024
First posted
Oct 8, 2024
StartActual
May 26, 2025
Primary completionActual
Feb 18, 2026
CompletionEst.
Oct 2026
Last update
Feb 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06630559
Lead sponsor
Celltrion
Responsible party
Sponsor
First posted
Oct 8, 2024
Start date
May 26, 2025
Primary completion
Feb 18, 2026
Completion
Oct 2026 (estimated)
Last update
Feb 23, 2026

Study contacts

Marek Krogulec
principal investigator · Rheumatology Clinic NZOZ Lecznica MAK-MED s.c.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion